BackHanda Pharmaceuticals Overview

Handa Pharmaceuticals Receivables

Handa Pharmaceuticals's receivables is $420M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$422.42M
↓ 15.92% YoYΔ $-79.97M vs prior year quarter

Peer trimmed avg / median

Loading

Handa Pharmaceuticals Receivables History

Loading

Handa Pharmaceuticals vs. peers: Receivables Comparison

Loading

Handa Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Handa Pharmaceuticals (6620.TWO) FAQ

The latest receivables for 6620.TWO is $420M as of June 2026. That compares with $500M in the prior-year period — down 15.9% year over year. Investors often review this figure alongside Handa Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6620.TWO's receivables moved from $500M to $420M — a 15.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Handa Pharmaceuticals's operating scale or balance-sheet position.

A receivables figure of $420M for 6620.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6620.TWO's receivables ($420M), review year-over-year change from $500M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.